Twin phase 3 trials (4311 treated) in asthma uncontrolled on ICS-LABA: budesonide-glycopyrronium-formoterol improved trough FEV1 (76 mL) and cut severe exacerbations versus combined budesonide-formoterol (IRR 0.86); vs BFFA alone the rate ratio was non-significant.
RCTn = 4,311
Papi et al. Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials